Revance to Participate in the UBS Global Healthcare Conference
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and
underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in
New York, NY.
Chief Financial Officer and Chief Business Officer, Lauren Silvernail, is scheduled to present on Tuesday, May 22 at 11:00am
ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with
plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting
neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel,
differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and
topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com."Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics,
Inc.
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert
(714) 325-3584
jherbert@revance.com
or
Burns McClellan, Inc.:
Ami Bavishi
(212) 213-0006
abavishi@burnsmc.com
or
MEDIA
General Media:
TOGORUN:
Mariann Caprino
(917) 242-1087
m.caprino@togorun.com
or
Trade Media:
Nadine Tosk
(504) 453-8344
nadinepr@gmail.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180515005135/en/